- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
Patent holdings for IPC class A61P 7/00
Total number of patents in this class: 2865
10-year publication summary
|
97
|
180
|
174
|
207
|
244
|
199
|
253
|
230
|
168
|
121
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 648 |
40 |
| Novartis AG | 10263 |
35 |
| The Regents of the University of California | 20720 |
33 |
| Global Blood Therapeutics, Inc. | 169 |
30 |
| Takeda Pharmaceutical Company Limited | 2715 |
26 |
| Acceleron Pharma Inc. | 341 |
24 |
| Children's Medical Center Corporation | 1956 |
21 |
| Jiangsu Hengrui Medicine Co., Ltd. | 694 |
18 |
| Bayer Pharma AG | 1014 |
17 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3299 |
17 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 712 |
16 |
| Daiichi Sankyo Company, Limited | 1893 |
15 |
| The University of Tokyo | 4352 |
15 |
| President and Fellows of Harvard College | 6091 |
14 |
| Vertex Pharmaceuticals Incorporated | 1584 |
14 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
14 |
| Vifor (International) AG | 145 |
14 |
| F. Hoffmann-La Roche AG | 7836 |
13 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3219 |
13 |
| Bristol-myers Squibb Company | 4729 |
12 |
| Other owners | 2464 |